DEFA14A: Relay Therapeutics Sets Date for Annual Stockholders Meeting, Outlines Key Proposals

Relay Therapeutics will hold its annual stockholders meeting on June 3, 2024, to elect directors, vote on executive compensation, and ratify the appointment of Ernst & Young LLP as the company's auditor.

Summary

• Relay Therapeutics will hold its Annual Meeting of Stockholders on June 3, 2024, at 1:30 PM Eastern Time.
• The meeting will be held live via the internet at www.proxydocs.com/RLAY.
• Stockholders of record as of April 4, 2024, are eligible to vote.
• The proposals include electing two Class I directors (Sanjiv K. Patel, M.D., and Linda A. Hill, Ph.D.) to serve until the 2027 annual meeting.
• Stockholders will also vote on an advisory resolution regarding the compensation of named executive officers.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, will be ratified.
• The board of directors recommends voting 'FOR' all three proposals.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating a neutral to slightly positive sentiment as it reflects the company's adherence to corporate governance practices.

Positives

• Stockholders have multiple options for accessing proxy materials and voting, including online, telephone, and email.
• The board clearly recommends voting 'FOR' all proposals, providing guidance to stockholders.

Industry Context

This is a standard proxy statement related to an annual meeting, a routine part of corporate governance for publicly traded companies.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will impact the company's governance and direction.
• The outcome of the votes will influence the composition of the board and the selection of the company's auditor.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold its Annual Meeting of Stockholders on June 3, 2024.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Relay Therapeutics, Directors, Executive Compensation, Ernst & Young, Auditor